Pfizer Announces Trial Updates for Investigational Hemophilia Gene Therapy
Pfizer recently announced positive top-line results from the phase 3 BENEGENE-2 clinical study, which is currently evaluating the investigational gene therapy fidanacogene elaparvovec for the treatment...
View ArticleNHF Announces 2023 Winter/Spring Wednesday Webinar Schedule
FOR IMMEDIATE RELEASE Ilana Ostrin Senior Director of Public Relations and Communicationsiostrin@hemophilia.org 212-328-3769 NHF Announces 2023 Winter/Spring Wednesday Webinar Schedule The free series...
View ArticleTakeda Announces Trial Results on Investigational Therapy for Ultra Rare...
Takeda recently announced favorable results from a phase 3 study of TAK-755, the company’s investigational enzyme replacement therapy for an ultra-rare blood disorder known as congenital thrombotic...
View ArticleBiomarin Provides Hemophilia A Clinical Development Program Updates
BioMarin recently shared a community update on their Hemophilia A Clinical Development Program for valoctocogene roxaparvovec, the company’s investigational gene therapy currently under review by the...
View ArticleNew FIX Chromogenic Assay Launched by Precision Biologics
Precision Biologic Inc., a company specializing in hemostasis diagnostics, recently announced that they have received the requisite clearance from the U.S. Food and Drug Administration (FDA) to launch...
View ArticleNHF & HFA Respond to New Blue Cross Blue Shield of Tennessee Formularies
FOR IMMEDIATE RELEASE Contact:Ilana Ostrin 212-328-3769
View ArticleNHF Responds to FDA's Proposed Blood Donation Changes
FOR IMMEDIATE RELEASE Contact: Ilana Ostrin 212-328-3769
View ArticleSanofi Announces New Efanesoctocog alfa Data Published in the NEJM
Sanofi recently announced newly published clinical trial data for efanesoctocog alfa, the company’s investigational recombinant factor VIII therapy (rFVIII) for the prevention of bleeding episodes in...
View ArticleWFH Gene Therapy Registry Goes Live
The World Federation of Hemophilia (WFH) has launched a new registry to help monitor the long-term safety and efficacy of hemophilia gene therapies in people with hemophilia across the globe.
View ArticleImportant Changes Coming to Your State Medicaid or CHIP Program
[This content was shared for public use by the Centers for Medicare & Medicaid Services]
View ArticleKopenitz family commits substantial funding to NHF health equity initiatives
This year, NHF celebrates its 75th anniversary. And in honor of this incredible milestone, NHF is welcoming a new era for the inheritable blood and bleeding disorders community by creating a more...
View ArticleStudy Suggests Significant Rates of Depression and Anxiety for Individuals...
While it is well understood that individuals with von Willebrand disease (VWD) will experience a variety bleeding episodes throughout their lifetime, the psychosocial impact of these symptoms has...
View ArticleAPLUS Coalition Members Unite to Issue New Joint Statement
Washington, D.C. - The APLUS Coalition, an alliance of patient advocacy organizations, has announced a new joint statement in a show of solidarity for those living with conditions requiring the use of...
View ArticleFDA Approves ALTUVIIIO™ for Hemophilia A Patients
The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO ™, formerly known as efanesoctocog alfa, for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as...
View ArticleNHF Public Policy February Monthly Update
During legislative session, NHF's chapter network, public policy staff, and the bleeding disorders community at large has been hard at work advocating across the United States! For the month of...
View ArticleNew FIX Chromogenic Assay Launched by Precision BioLogic
Precision BioLogic Inc., a company specializing in hemostasis diagnostics, recently announced that they have received the requisite clearance from the U.S. Food and Drug Administration (FDA) to launch...
View ArticleuniQure Announces Published Trial Results for Approved Gene Therapy
uniQure recently announced publication of the clinical trial results associated with approval of the hemophilia gene therapy product
View ArticleNHF Public Policy February Monthly Update
During legislative session, NHF's chapter network, public policy staff, and the bleeding disorders community at large has been hard at work advocating across the United States! For the month of...
View ArticleNational Hemophilia Foundation Names Michael Recht, MD, PhD, MBA, as Chief...
FOR IMMEDIATE RELEASEMEDIA CONTACT:iostrin@hemophilia.org
View ArticleVenture Philanthropy Fund to Accelerate the Development of Transformational...
FOR IMMEDIATE RELEASE Renee Peck Pathway to Curesrpeck@pathwaytocures.org 212-328-3790 National Hemophilia Foundation Launches “Pathway to Cures,” a Venture Philanthropy Fund to Accelerate the...
View Article